Evaluate

April 04, 2019

Sillajen and Transgene bid to revive the oncolytic virus craze

The industry’s most advanced oncolytic virus project, Pexa-Vec, faces a make-or-break pivotal study readout.

February 21, 2018

Merck & Co makes biggest oncolytic virus bet since Amgen in 2011

August 08, 2017

Pamrevlumab comes off the bench to deliver for Fibrogen

July 03, 2017

Therapy focus – Opdivo and Livatag could add to liver cancer options

April 28, 2017

Snippets roundup: Sanofi diabetes disappointment, and Amgen pullback signals CGRP caution

December 13, 2016

Setbacks fail to stifle oncolytic virus business development

October 12, 2016

Transgene pins hopes on cancer vaccine combos

August 15, 2016

Therapy focus – Hepatitis B developers try to repeat Gilead’s hep C trick

June 29, 2016

Bayer quietly claims its liver cancer prize